Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
Alexander E. Perl(University of Pennsylvania), Mark J. Levis(Sidney Kimmel Cancer Center), Robert K. Stuart(Memorial Sloan Kettering Cancer Center), Raoul Tibes(BioNTech (Germany)), Jessica K. Altman(Northwestern University), Christoph Röllig(University Hospital Carl Gustav Carus), Stephen A. Strickland(Vanderbilt University), Gary J. Schiller(Fred Hutch Cancer Center), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Alexander I. Spira(Virginia Cancer Specialists), Andreas Neubauer(RWTH Aachen University), Maria R. Baer(University of Maryland, Baltimore), Harry P. Erba(Michigan Center for Translational Pathology), Joseph G. Jurcic(Memorial Sloan Kettering Cancer Center), Celalettin Üstün(Rush University Medical Center), Giovanni Martinelli(University of Bologna), Ellen K. Ritchie(Cornell University), Erkut Bahceci(Astellas Pharma (United States)), Chaofeng Liu(Fujian Normal University), Mark R. Litzow(Mayo Clinic in Arizona), Stan Gill(Astellas Pharma (United States)), Catherine C. Smith(University of California, San Francisco), David F. Claxton(The University of Texas MD Anderson Cancer Center), Stuart L. Goldberg(Center for Discovery), Jörge E. Cortes(Augusta University Health)
Cited by 493
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k